Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606125 · ClinicalTrials.gov registry record · Phase 1
Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00606125 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 16 participants.
The verdict
NCT00606125, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to: 1. Evaluate how the body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin, 2. Measure the blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and 3. To determine the safety of sorafenib.
Interventions
- DRUG Nexavar (Sorafenib, BAY43-9006)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606125
The ClinicalTrials.gov registry entry for NCT00606125 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nexavar (Sorafenib, BAY43-9006) is the first listed.
NCT00606125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00606125 about?
NCT00606125 is a clinical study titled "Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors". The purpose of this study is to: 1. Evaluate how the body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin, 2. Measure the blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and 3. To determine the safety of sorafe...
What is the current status of trial NCT00606125?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2007-05. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00606125?
The interventions under investigation include: Nexavar (Sorafenib, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00606125?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.